Live
- Bihar: Bypolls for Tirhut Graduate MLC Constituency to be held on Dec 5
- Indonesia seeks 120 million USD in investment by 2025
- Van Nistelrooy 'hoping' for Man Utd injury boost ahead of Europa League clash
- Vietnam strives to be among top three ASEAN countries in industrial competitiveness
- New antibody treatment boosts immune response against tumor: study
- Supreme Court judgment tomorrow on validity of UP Madarsa Act
- Uttar Pradesh enhances support for teachers with revised transfer policy
- Tokyo Stock Exchange to extend trading hours by 30 minutes
- 1,000 Chhath Puja ghats getting ready: Delhi CM Atishi
- Nvidia CEO wants SK hynix to advance supply of HBM4 chips by 6 months
Biological E. reduces price of its COVID-19 vaccine from Rs 840 to whopping Rs 250 per dose
Pharmaceuticals firm Biological E. Ltd (BE) on said it has reduced the price of its COVID-19 vaccine Corbevax to Rs 250 from Rs 840 a dose, inclusive of GST, for private vaccination centres.
Pharmaceuticals firm Biological E. Ltd (BE) on said it has reduced the price of its COVID-19 vaccine Corbevax to Rs 250 from Rs 840 a dose, inclusive of GST, for private vaccination centres.
It would result in end users paying a price of Rs 400 a dose, including taxes and administration charges, the company said in a statement.
Previously, in private vaccination centres the overall cost to end users of the vaccine was Rs 990 a dose, including taxes and administration charges, it added.
In March this year when the inoculation of children in the age group of 12 to 14 years against COVID-19 commenced in the country, Corbevax vaccine was used and its price was fixed at Rs 145 for government vaccination programme.
"BE has lowered the price of its vaccine with the aim of making it more affordable and help increase the reach to protect the maximum number of children against the virus," the company said.
In April this year India's drug regulator had granted Emergency Use Authorisation (EUA) for Biological E's Corbevax for children in 5 to 12 years group along with Bharat Biotech's Covaxin for children in the age group of 6 to 12 years.
BE had collaborated with Texas Children's Hospital and Baylor College of Medicine in the development of Corbevax. Prior to receiving EUA for vaccination, the company said it conducted Phase II and III multi-centre clinical trials in 624 children aged 5-12 and 12-18.
